Table 7.

Visual acuity and visual field achieved at 15 months and 2–5 years of follow-up, and overall final follow-up in eyes without macular edema

Visual assessment	Non-ischemic CRVO	Ischemic CRVO as first diagnosis	Ischemic CRVO converted from non-ischemic
Visual Acuity
15 months*	(n=93)	(n=9)	(n=4)
20/15–20/20	43 (46%)	1 (11%)	--
20/25–20/30	25 (27%)	0 (0%)	--
20/40–20/60	9 (10%)	1 (11%)	--
20/70–20/100	5 (5%)	0 (0%)	0 (0%)
20/200–400	10 (11%)	0 (0%)	1 (25%)
CF or worse	1 (1%)	7 (78%)	3 (75%)
2–5 years	(n=146)	(n=13)	(n=10)
20/15–20/20	61 (42%)	0 (0%)	--
20/25–20/30	29 (20%)	0 (0%)	--
20/40–20/60	20 (14%)	0 (0%)	--
20/70–20/100	9 (6%)	0 (0%)	1 (10%)
20/200–400	25 (17%)	5 (38%)	3 (30%)
CF or worse	2 (1%)	8 (62%)	6 (60%)
Final@	(n=316)	(n=26)	(n=10)
20/15–20/20	138 (44%)	0 (0%)	--
20/25–20/30	54 (17%)	1 (3%)	--
20/40–20/60	45 (14%)	2 (6%)	--
20/70–20/100	26 (8%)	1 (3%)	1 (10%)
20/200–400	46 (15%)	9 (35%)	4 (40%)
CF or worse	7 (2%)	13 (50%)	5 (50%)
Visual Field Defect
15 months*	(n=90 eyes)	(n=9)	(n=3)
Minimal	81 (90%)	0 (0%)	0 (0%)
Mild	8 (9%)	2 (22%)	1 (33%)
Moderate	0 (0%)	3 (33%)	0 (0%)
Marked	0 (0%)	2 (22%)	1 (33%)
Severe	1 (1%)	2 (22%)	1 (33%)
2–5 years	(n=142 eyes)	(n=17)	(n=12)
Minimal	122 (86%)	0 (0%)	1 (8%)
Mild	18 (13%)	3 (18%)	4 (33%)
Moderate	1 (1%)	7 (41%)	1 (8%)
Marked	1 (1%)	4 (23%)	4 (33%)
Severe	0 (0%)	3 (18%)	2 (17%)
Final@	(n=312 eyes)	(n=28)	(n=12)
Minimal	271 (87%)	1 (4%)	1 (8%)
Mild	24 (8%)	4 (14%)	5 (42%)
Moderate	13 (4%)	9 (32%)	0 (0%)
Marked	3 (1%)	6 (21%)	3 (25%)
Severe	0 (0%)	8 (29%)	3 (25%)

^*±12 weeks

^@of those with at least 3 months follow-up; includes all eyes regardless of time from onset of the first visit

CF = counting fingers; CRVO=Central retinal Vein Occlusion